Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer

Fitzsimmons, Deborah; Johnson, C. D.; George, Steve; Payne, Sheila; Sandberg, A; Bassi, Claudio; Beger, Hans G.; Birk, Dieter; Büchler, Markus W.; Dervenis, Christos; Cruz, Laureano Fernández; Frieß, Helmut; Grahm, Anna-Lena; Jeekel, J.; Laugier, R.; Meyer, Douglas; Singer, Marybeth; Tihanyi, Tibor

doi:10.1016/s0959-8049(99)00047-7

Cited by 233 publications

(158 citation statements)

References 7 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30, version 3.0) [22] including the QLQ-PAN26, a specific module for pancreatic cancer [23]. In line with the study objectives, this report only presents results from dietary intake, QLQ-PAN26 and the ESAS.…”

Section: Symptom Assessmentmentioning

confidence: 99%

“…A score of 4 or higher was identified as moderate to severe intensity [24]. The QLQ-PAN26 includes 26 items covering symptoms related to PC and its treatment (pancreatic pain, dietary changes, altered bowel habits, indigestion, flatulence, oral dryness, taste changes, cachexia and jaundice) as well as emotional problems (body image, fear of future health, healthcare satisfaction and sexuality) [23]. For this study we only used the eight items/scales covering symptoms most likely to influence dietary intake; pancreatic pain, dietary changes, altered bowel habits, indigestion, flatulence, oral dryness, taste changes and cachexia [25,26].…”

Section: Symptom Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Symptoms in advanced pancreatic cancer are of importance for energy intake

Bye

Jordhøy

Skjegstad

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

Purpose: Cancer cachexia and low energy intake (EI) probably contribute to weight loss in advanced pancreatic cancer (PC). However, little is known about the actual EI in this disease. Aims were to assess EI, weight loss and symptoms during the disease course and investigate associations between symptoms and EI.Methods: Thirty-nine patients (21 males) with advanced PC were consecutively included and followed every 4 weeks until the end of life. A 24-hour dietary recall was used to assess EI. The Edmonton Symptom Assessment System (ESAS) and the PC-specific health-related quality of life questionnaire (QLQ-PAN26) were used for symptom assessment. Conclusion:In this study several symptoms influenced EI negatively. Low EI did not completely explain weight loss in this patient group, but careful monitoring and early follow-up of symptoms may be important interventions to reduce weight loss in advanced PC.

show abstract

Section: Symptom Assessmentmentioning

confidence: 99%

Section: Symptom Assessmentmentioning

confidence: 99%

Symptoms in advanced pancreatic cancer are of importance for energy intake

Bye

Jordhøy

Skjegstad

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…11 A reliable disease-specific quality-of-life questionnaire has been developed in Europe, which should enable the impact of pancreatic cancer to be assessed, but until then, the so-called intangible costs remain essentially unaccounted. 12 General cost evaluations have been reported in the USA. The total cost of cancer care in the USA in 1999 was reported by one group to be about US$146 billion and it was estimated that pancreatic cancer accounted for approximately 1.8% (US$2.6 billion) of the overall cost, while another estimate suggested the total cost could be as high as US$4.9 billion, the latter including some indirect costs.…”

Section: Financial Burdenmentioning

confidence: 99%

Pancreatic diseases

McNamara

2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

“…Benefits in terms of survival time and the alleviation of symptoms may be outweighed by the cost of toxicity and deterioration in QoL. 104 There is some evidence to support the role of chemotherapy in advanced pancreatic cancer. In 1996, Glimelius and colleagues reported on 90 patients with advanced pancreatic and biliary cancer who were randomised to receive chemotherapy (5-FU, leucovorin with or without etoposide) plus BSC or BSC alone.…”

Section: Quality Of Life Issuementioning

confidence: 99%

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

Ward

Morris²,

Bansback³

et al. 2001

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Rapid reviews are completed in a limited time to inform the appraisal and guideline development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidelines produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 00/10/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors.Criteria for inclusion in the HTA monograph series Reports are pu...

show abstract

Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer

Cited by 233 publications

References 7 publications

Symptoms in advanced pancreatic cancer are of importance for energy intake

Symptoms in advanced pancreatic cancer are of importance for energy intake

Pancreatic diseases

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

Contact Info

Product

Resources

About